This is an aggregated industry headline. Read the full story at Drug Channels →
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to spend the summer than reading about new pharmacy resources in the Drug Channels News Roundup? In this issue: The New Biosimilar Launch Playbook Factors Adding to Part D Cost Trends Rural vs. N
By Drug Channels
· Jul 28, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp's role to cover the offic…
The WeekFierceBiotech ↗
Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research…
The WeekBriefing
FDA approval of Otsuka’s Simtriyo gives the company a first-in-class ADHD asset. The real question now is whet…